Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31
Rhea-AI Summary
Precigen (Nasdaq: PGEN) announced a virtual fireside chat with H.C. Wainwright on March 31, 2026 from 11:00 AM to 12:00 PM ET. Helen Sabzevari, PhD, President and CEO, and Phil Tennant, Chief Commercial Officer, will participate.
Participants can view event details and access the webcast via Precigen's Events & Presentations page at investors.precigen.com/events-presentations.
Positive
- None.
Negative
- None.
News Market Reaction – PGEN
In the Mar 30 session, PGEN declined 11.44%, reflecting a significant negative market reaction. Argus tracked a peak move of +16.2% during that session. Argus tracked a trough of -5.8% from its starting point during tracking. Our momentum scanner triggered 76 alerts that day, indicating high trading interest and price volatility. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 25 | Earnings and updates | Positive | +25.5% | Full-year 2025 results and PAPZIMEOS commercialization and regulatory milestones. |
| Mar 11 | Earnings date notice | Neutral | -4.1% | Announcement of date and call details for upcoming full-year 2025 results. |
| Jan 20 | Clinical consensus news | Positive | -0.5% | Independent consensus recommending PAPZIMEOS as new first-line RRP standard of care. |
| Jan 12 | Commercial momentum | Positive | -9.9% | Update on rapid PAPZIMEOS commercialization, coverage and operational readiness at JPM. |
| Jan 05 | Conference participation | Positive | +8.8% | Notice of CEO presentation and fireside chat at J.P. Morgan Healthcare Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows mixed reactions: strong gains on major earnings and conference updates, but occasional selloffs or flat trading after otherwise positive commercialization news.
Over the last six months, PGEN transitioned to a commercial-stage story centered on PAPZIMEOS. Earnings on Mar 25, 2026 with commercial and regulatory milestones saw a 25.48% gain, while a J.P. Morgan conference presentation on Jan 5, 2026 rose 8.85%. Other positive commercialization updates on Jan 12 and expert consensus news on Jan 20 coincided with declines, highlighting that good fundamental news has not always produced supportive price action. Today’s routine fireside chat notice fits the ongoing investor-relations cadence.
Key Terms
immuno-oncology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Participants may view details for this event on Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.
Precigen: Advancing Medicine with Precision®
Precigen (Nasdaq: PGEN) is a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, information relating to the Company's business and business plans, the success of efforts to commercialize PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults including the revenue that the Company expects to realize from such efforts, the Company's ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS, the ability of PAPZIMEOS to treat RRP, the Company's future financial and operational results including the Company's ability to reach cash flow break-even, and the Company's ability to commence clinical studies or complete ongoing clinical studies for the Company's clinical and pre-clinical stage candidates. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.
Investor Contact:
Steven M. Harasym
Tel: +1 (202) 365-2563
investors@precigen.com
Media Contact:
Donelle M. Gregory
press@precigen.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-to-participate-in-a-fireside-chat-with-hc-wainwright-on-march-31-302728209.html
SOURCE Precigen, Inc.